MDL 62,879 (formerly GE 2270 A) is a novel antibiotic active against Gram-positive bacteria by inhibiting protein synthesis. MDL 62,879 is not active against Gram-negative bacteria, but inhibits cell-free protein synthesis in extracts from Escherichia coli, and shows a high binding affinity for its elongation factor Tu (EF-Tu). We prepared ribosomes and protein-synthesis elongation factors from three sources: E. coli, Bacillus subtilis, and a strain of B. subtilis selected for resistance to MDL 62,879 (strain G1674). Homologous and he.terologous reconstituted systems were used to compare the effects of MDL 62,879 and of efrotomycin, an EF-Tu inhibitor of the kirromycin class, which is inactive against both B. subtilis and E. coli. We showed that in cell-free protein synthesis: (a) E. coli was sensitive to both MDL 62,879 and efrotomycin; (b) B. subtilis was sensitive to MDL 62,879, but not to efrotomycin; (c) B. subtilis G1674 was resistant to both antibiotics. In the E. coli system and in the system from vild-type B. subtilis, inhibition by MDL 62,879 was reversed upon addition of purified EF-Tu from B. subtilis G1674. This demonstrates that the antibiotic acts by inhibition of EFTu. In contrast, extracts from B. subtilis failed to restore activity in an efrotomycin-inhibited E. coli system. Dominance or resistance to MDL 62,879 and of sensitivity to efrotomycin in heterologous cell-free protein synthesis confirms that inhibition of EF-Tu by the two antibiotics is mediated by different mechanisms of action.
INTRODUCTION
MDL 62,879 (GE 2270 A) is a recently discovered antibiotic isolated from fermentation broth of a strain of Planobispora rosea (Selva et al., 1991) . It has been characterized as an inhibitor of bacterial elongation factor Tu (EF-Tu), and its interaction with this protein has been described (Selva et al., 1991; Anborgh & Parmeggiani, 1991) . MDL 62,879 differs in chemical structure, in nature of interaction with EF-Tu and in spectrum of antimicrobial activity from kirromycin, another class of EF-Tu inhibitors (Selva et al., 1991; Parmeggiani & Swart, 1985) . MDL 62,879 appears to inhibit aminoacyl-tRNA binding to EF-Tu (Anborgh & Parmeggiani, 1991) , whereas kirromycin inhibition involves stimulation of intrinsic GTPase activity and the formation of a non-dissociable ribosome-EF-Tu complex (Wolf et al., 1974 (Wolf et al., , 1977 .
MDL 62,879 is active against Gram-positive bacteria and Gram-negative aerobes (Selva et al., 1991) , whereas kirromycins have no activity against some species of Gram-positive bacteria, such as staphylococci, enterococci and Bacillus subtilis (Frost et al., 1976) . Neither MDL 62,879 nor kirromycins are active against E. coli, but cell-free protein-synthesis systems from this micro-organism are highly sensitive to these antibiotics (Anborgh & Parmeggiani, 1991; Chinali et al., 1976 in Traub et al. (1971) . Briefly, cells were washed and suspended in 20 mM-Tris/HCI, pH 7.9, containing 10 mM-MgC12, 5 mMdithiothreitol and 0.2 mM-phenylmethanesulphonyl fluoride (buffer A) and broken by sonication in ice (10 cycles of 30 s with intervals of 30 s). Cell debris was removed by centrifugation at 30000 g (30 min, 4°C). Ribosomes were pelleted by centrifugation at 100000 g for 4 h at 2 'C. The supernatant (S-100) was concentrated by (NH4)2SO4 fractionation as described in Ravel & Shorey (1971) . The 35-60 %-(NH4)2SO4 precipitate was kept and dialysed against buffer A + 0.35 M-NaCl (buffer B). This fraction (termed S-100') was used as the source of proteinsynthesis elongation factors and for purification of EF-Tu. Poly(U)-directed poly(Phe) synthesis was performed in 30 mMTris/HCI, pH 7.9, containing 10 mM-MgCI2, 80 mM-NH4Cl, 0.8 mM-ATP, 1 mM-GTP, 3 mm-DTT and 0.8 jug of phenylalanine-specific tRNA from E. coli, 0.6 ,uCi of Abbreviations used: EF-Tu, elongation factor Tu; poly(Phe), polyphenylalanine; IC50, 50 %-inhibitory concentration.
* To whom correspondence should be addressed. Incubation was for 30 min at 30°C in a final volume of 0.1 ml. Samples were precipitated with ice-cold trichloroacetic acid (final concn. 5 %, w/v) and heated for 10 min at 80 'C. The acidprecipitated material was collected on glass-fibre filters using a cell-harvester (LKB), and radioactivity was determined in a Beta-plate scintillation counter (Pharmacia).
EF-Tu purification EF-Tu from E. coli was purified as described in Lebermann et al. (1980) . B. subtilis EF-Tu was purified by loading the S-100' on to a GDP-Sepharose column (1 cm x 5 cm) pre-equilibrated with buffer B and washed with 5 vol. of the same equilibration buffer before elution of EF-Tu with 2 mM-GDP in buffer B. The purification steps were monitored by SDS/PAGE (8-25 % polyacrylamide gradient gel) in the Phastgel system (Pharmacia). Control incorporated 4.6 pmol of phenylalanine.
(a) (Fig. la) . For efrotomycin the IC50 in the E. coli system was 0.12 mg/l, whereas poly(Phe) synthesis performed with B. subtilis extracts and in the mixed system was unaffected by antibiotic concentrations up to 200 mg/l (Fig. lb) . In cell-free extracts from B. subtilis G1674 both MDL 62,879 and efrotomycin were inactive at up to 100 mg/l (Fig. 2) . These results suggest that the lack of susceptibility of wild-type B. subtilis to efrotomycin is due to an intrinsically resistant EFTu, and that resistance to MDL 62,879. in B. subtilis G1674 was due to alteration of a protein-synthesis factor, presumably EF-Tu.
EF-Tu purification
To determine whether the mutation leading to MDL 62,879-resistance was indeed in the gene encoding EF-Tu, the protein After 5 min at 30°C, 2,ug of S-00' from E. coli (E]) or from B. subtilis G1674 (A) was added. The E. coli system in the absence of antibiotics served as the control (0). was purified from both the wild-type and the resistant strains of B. subtilis. Purification of EF-Tu was monitored by SDS/PAGE.
As shown in Fig. 3 , EF-Tu represented up to 10 % of total protein in the S-100' preparations from B. subtilis used in poly(U) assays; after GDP-Sepharose chromatography EF-Tu represented more than 90 O/, of the protein detectable in the gel. When 5 pmol of pure EF-Tu from MDL 62, subtilis G1674 was added to sensitive cell-free systems from either B. subtilis A.T.C.C. 6633 (Fig. 4a ) or E. coli (Fig. 4b) , the IC50 of MDL 62,879 increased from 0.12 to > 100 mg/l. Thus resistance to MDL 62,879 is mediated by an alteration of the gene encoding EF-Tu. Addition of 5 pmol of pure. EF-Tu from the sensitive B. subtilis strain increased the IC50 only slightly, from 0.12 to 0.15 mg/I in the E. coli system and from 0.12 to 0.18 mg/l in B. subtilis A.T.C.C. 6633. This is probably an effect of increasing the stoichiometric ratio of EF-Tu to MDL 62,879. efrotomycin-resistance, S-100' from B. subtilis G1674 was added to a cell-free protein-synthesis system from E. coli containing 10 mg of either MDL 62,879 or efrotomycin/l. As shown in Fig.  5 , the S-100' from G1674 led to a complete reversal of MDL 62,879 inhibition after a short lag period (Fig. 5a ). By contrast, efrotomycin inhibition was not reversed upon addition of G1674 S-100' (Fig. 5b) . DISCUSSION B. subtilis strain G1674, selected for resistance to MDL 62,879, also demonstrated resistance in cell-free poly(U)-directed poly(Phe) synthesis. This indicates that resistance was the result of an altered target of the antibiotic, and not due to decreased permeability. Indeed, the addition of purified EF-Tu from this strain reversed MDL 62,879 inhibition of sensitive cell-free protein-synthesis systems from E. coli and wild-type B. subtilis. This suggests that resistance is caused by mutation in the gene encoding EF-Tu and, consequently, that the antimicrobial activity of MDL 62,879 is in fact mediated by its interaction with EF-Tu.
B. subtilis is naturally resistant to kirromycins; cell-free poly(U)-directed poly(Phe) synthesis from this organism was insensitive to 200 mg of efrotomycin/l. This result supports the observation by Smith & Paress (1978) that EF-Tu from wild-type B. subtilis was inhibited only by high concentrations of kirromycins (100 mg/l). We are unable to explain the apparent kirromycin-sensitivity of B. subtilis EF-Tu reported by Woerner et al. (1983) .
Studies on other Gram-positive bacteria (Staphylococcus aureus, lactobacilli) demonstrate that, in most cases, kirromycin resistance is mediated by EF-Tu (Hall et al., 1989; Woerner & Wolf, 1982; Woemer et al., 1983) , whereas in E. coli resistance is due to lack of penetration into the cell. Although the tuf genes, which encode EF-Tu, appear to be highly conserved among bacteria (Filer & Furano, 1980) , the kirromycin-binding site may be less conserved than other domains of the protein. However, the degree of heterogeneity might still be small, since a single amino acid substitution in an E. coli EF-Tu leads to a complete loss of affinity of kirromycins for the protein (Parmeggiani & Swart, 1985) .
B. subtilis G1674 maintained the resistance to efrotomycin of the parent strain. When S-100' factor from this strain was added to a cell-free system from E. coli sensitive to both kirromycins and MDL 62,879, inhibition by MDL 62,879, but not by efrotomycin, was reversed. Dominance of sensitivity to efrotomycin when both a sensitive and a resistant EF-Tu are present in a cell-free assay is probably due to stabilization of the EF-Tu-ribosome complex by kirromycins (Wolf et al., 1974) , and is consistent with the fact that it is necessary to mutate both of the duplicate tufgenes which encode EF-Tu in E. coli in order to obtain a kirromycin-resistant cell-free protein-synthesis system (Van der Weide et al., 1980) . Dominance of resistance observed for MDL 62,879 inhibition confirms that its mechanism of action differs from that of the kirromycin group, and is consistent with the mode of action proposed by Anborgh & Parmeggiani (1991 
